These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 10837554)

  • 1. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction.
    Shen DD; Kunze KL; Thummel KE
    Adv Drug Deliv Rev; 1997 Sep; 27(2-3):99-127. PubMed ID: 10837554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach.
    Brussee JM; Yu H; Krekels EHJ; Palić S; Brill MJE; Barrett JS; Rostami-Hodjegan A; de Wildt SN; Knibbe CAJ
    Pharm Res; 2018 Jul; 35(9):182. PubMed ID: 30062590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
    Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
    Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of human pharmacokinetics--gut-wall metabolism.
    Fagerholm U
    J Pharm Pharmacol; 2007 Oct; 59(10):1335-43. PubMed ID: 17910807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.
    Galetin A; Houston JB
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1220-9. PubMed ID: 16763093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.
    Galetin A; Hinton LK; Burt H; Obach RS; Houston JB
    Curr Drug Metab; 2007 Oct; 8(7):685-93. PubMed ID: 17979656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-pass elimination. Basic concepts and clinical consequences.
    Pond SM; Tozer TN
    Clin Pharmacokinet; 1984; 9(1):1-25. PubMed ID: 6362950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
    Kharasch ED; Hoffer C; Whittington D; Sheffels P
    Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
    Paine MF; Khalighi M; Fisher JM; Shen DD; Kunze KL; Marsh CL; Perkins JD; Thummel KE
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1552-62. PubMed ID: 9400033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
    Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.
    Jones CR; Hatley OJ; Ungell AL; Hilgendorf C; Peters SA; Rostami-Hodjegan A
    AAPS J; 2016 May; 18(3):589-604. PubMed ID: 26964996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats.
    Kanazu T; Okamura N; Yamaguchi Y; Baba T; Koike M
    Xenobiotica; 2005 Apr; 35(4):305-17. PubMed ID: 16019953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates.
    Brussee JM; Yu H; Krekels EHJ; de Roos B; Brill MJE; van den Anker JN; Rostami-Hodjegan A; de Wildt SN; Knibbe CAJ
    CPT Pharmacometrics Syst Pharmacol; 2018 Jun; 7(6):374-383. PubMed ID: 29745466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction.
    Gertz M; Houston JB; Galetin A
    Drug Metab Dispos; 2011 Sep; 39(9):1633-42. PubMed ID: 21632965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.
    Gertz M; Harrison A; Houston JB; Galetin A
    Drug Metab Dispos; 2010 Jul; 38(7):1147-58. PubMed ID: 20368326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.